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Abstract
Ectopic epigenetic mechanisms play important roles in facilitating tumorigenesis. Here, we first demonstrated that
ANKDD1A is a functional tumor suppressor gene, especially in the hypoxia microenvironment. ANKDD1A directly
interacts with FIH1 and inhibits the transcriptional activity of HIF1α by upregulating FIH1. In addition, ANKDD1A
decreases the half-life of HIF1α by upregulating FIH1, decreases glucose uptake and lactate production, inhibits
glioblastoma multiforme (GBM) autophagy, and induces apoptosis in GBM cells under hypoxia. Moreover, ANKDD1A is
highly frequently methylated in GBM. The tumor-specific methylation of ANKDD1A indicates that it could be used as a
potential epigenetic biomarker as well as a possible therapeutic target.
Introduction
The classic hallmark of human cancer genomes is aberrant
DNA methylation, including the genome-wide DNA
hypomethylation and hypermethylation of CpG island-
associated gene promoters. The latter leads to the epigenetic
silencing of tumor suppressor genes, thereby facilitating the
initiation and progression of cancer [1]. DNA methylation
alterations have been widely reported in human glioma [2],
one of the major central nervous system diseases that ranks
in the top place in the incidence of primary intracranial
tumors and level of malignancy.
Several genes were found to be repressed by promoter-
associated CpG island hypermethylation in human GBM
and other glioma subtypes [3]. For example, hyper-
methylation of the MGMT promoter-associated CpG
island has been shown in a large percentage of GBM
patients, and patients with MGMT hypermethylation
showed sensitivity to alkylating agents such as temozo-
lomide [4]. Interestingly, hypermethylation can also be
genetically encoded; mutations in some genes correlated
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positively with hypermethylation (e.g., IDH1, TET, and
BRAF), indicating the existence of a complex glioma
CpG island methylation phenotype (gCIMP) [5, 6]. Thus,
there is currently great interest in characterizing aberrant
DNA methylation in human glioma tumors to identify
aberrantly functioning molecular pathways and tumor
subtypes. Moreover, the hypermethylation of aberrant
tumor suppressor genes is not only a mechanism about
tumor initiation, but also a biomarker for tumor diagnosis
and prognosis prediction [7, 8].
Hypoxia conditions are caused in many solid tumors
(including high-grade glioma) by abnormal structure and
function of the micro-vessels. Tumor hypoxia has been
often associated with resistance to cancer treatment,
increased risk of invasion and metastasis, and poor prog-
nosis [9]. Because hypoxia-inducible factor 1α (HIF1α) is
the major regulator of tissue oxygen homeostasis and
HIF1α expression closely correlates with tumor growth and
invasion [10], HIF1α is considered to be responsible for
hypoxia-mediated cancer progression.
In previous studies, we adopted Methyl–DNA immuno-
precipitation (MeDIP) and NimblegenCpG promoter
microarrays to identify differential DNA methylation
sequences between primary glioma and normal brain tissue
samples. We have previously identified nine new hyper-
methylated genes and six new hypomethylated genes in
glioma [11]. We have reported the functions of some genes
in glioma, including LRRC4 [12–14], CPEB1 [15], LMO3
[16], and PRDM16 [17].
Here, we reported a new hypermethylated gene,
ANKDD1A (ankyrin repeat and death domain-containing
1A), which acts as a tumor suppressor in GBM, especially
under hypoxia. ANKDD1A is located at 15q22.31 and
contains nine ankyrin repeats and one death domain. The
ankyrin repeat is one of the most common protein–protein
interaction motifs in nature, and the repeat has been found
in proteins of diverse functions, such as transcriptional
activator, transporters, inflammatory responses, and signal
transducers [18–21]. We confirmed for the first time that
ANKDD1A directly interacted with the hypoxia-inducible
factor 1 alpha subunit inhibitor (HIF1AN, also known as
FIH1), which hydroxylates the Asn803 residue in the C-
terminal-activating domain (C-TAD) of HIF1α and inhibits
the transactivation function of HIF1α [22]. In addition,
FIH1 binds to von Hippel–Lindau (VHL) tumor suppressor
protein, which also functions as a transcriptional cor-
epressor inhibiting HIF-1α transactivation [23]. Our find-
ings revealed that the regain of ANKDD1A expression
resulted in reduced transactivation function and stability of
HIF1α, which suppressed GBM cells from adapting to
hypoxia, inhibited cell autophagy and induced apoptosis in
hypoxic microenvironment.
Results
Aberrant promoter hypermethylation conferred
decreased expression of ANKDD1A in glioma
The TCGA database analysis (G4502A) indicated that
ANKDD1A had decreased the expression in glioma com-
pared with normal brain tissues (Fig. 1a), and this expres-
sion pattern was further confirmed by real-time PCR in
glioma tissues (n= 27) and normal brain tissues (n= 10)
(Fig. 1b). Most tumor samples had low ANKDD1A
expression levels (17/27), and others had relatively medium
or high expression levels (10/27). However, almost all of
the normal brain tissues had medium or high ANKDD1A
expression levels (9/10), but only 1/10 had a low
ANKDD1A expression level. Kaplan–Meier analysis also
demonstrated that there were longer survival times for
glioma patients with relatively high ANKDD1A than for
those with lower ANKDD1A expression. Thus, high
ANKDD1A levels act as a favorite prognosis factor for
glioma patients (Fig. 1c). The methylation of DNA is
generally regarded as one of the most important epigenetic
modifications that lead to gene silencing. By MethPrimer
analysis, we found that the ANKDD1A promoter contained
a CpG island (region −400 bp to +400 bp from transcrip-
tion start site; Fig. 1d), indicating that hypermethylation
may cause the decreased expression of ANKDD1A in
glioma. Thus, we further designed bisulfite sequencing PCR
(BSP) and methylation-specific PCR (MSP) to validate the
hypermethylation of ANKDD1A in glioma. Methylation-
specific PCR showed that ANKDD1A was hypermethylated
in most glioma tissues (12/14) but only partially methylated
in normal brain tissues (1/8) (Fig. 1e). Similarly, using high-
resolution bisulfite genomic sequencing to analyze the
methylation state in 33 CpG sites within the CpG island of
the ANKDD1A gene, we found that there were more (20/
33) methylated CpG sites in the ANKDD1A gene promoter
in glioma compared to normal brain tissues (Fig. 1f). Next,
we investigated whether pharmacologic demethylation
restored ANKDD1A expression. Glioma cells were treated
with the DNA methyltransferase inhibitor 5-aza-2-
deoxycytidine. The treatment increased unmethylated
alleles (Fig. 1g), accompanied by an increase in ANKDD1A
mRNA and protein expression (Fig. 1h, i). Overall, these
results demonstrated that CpG hypermethylation at the
ANKDD1A promoter region directly contributed to the
decreased expression of ANKDD1A in glioma.
Ectopic expression of ANKDD1A reduced the
proliferation and invasion of astrocytoma cells
Ectopic expression of ANKDD1A (Fig. 2a) in U251 and
U87 cells suppressed GBM cell proliferation (Fig. 2b).
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Fig. 1 Hypermethylation of ANKDD1A in glioma and restoration of
ANKDD1A expression by demethylation treatment. a Analysis of
ANKDD1A expression in TCGA glioma gene expression data. The
expression of ANKDD1A is much lower in glioma than in normal
brain tissue. *P < 0.05. b Real-time qPCR was used to detect the
expression of ANKDD1A in glioma. The expression of ANKDD1A is
much lower in glioma than in normal brain tissues. **P < 0.01. c The
correlation between ANKDD1A expression in glioma and the OS of
the glioma patients. The glioma patients with higher ANKDD1A
expression had a favorable survival time. The Kaplan–Meier method
was used for this analysis. d Schematic structure of the CpG island of
ANKDD1A, exons, methylation-specific PCR primer sites, and
bisulfite genomic sequencing region. Each short vertical line in the
bottom panel is one CpG site. e Methylation status of the ANKDD1A
promoter in primary glioma tissues was analyzed by methylation-
specific PCR. N normal tissue; Primary glioma tissues: samples 1–10
are GBM, samples 11–12 are grade II astrocytoma, samples 13–14 are
grade III astrocytoma. M methylated; U unmethylated. f Methylation
was analyzed by bisulfite genomic sequencing analysis of 33 CpG
sites within the ANKDD1A promoter CpG island. N normal tissue, T
tumor tissue. T4, T5, T7, and T9 are GBM samples. Each circle is one
CpG site, and filled circles are methylated CpG sites. g–i Demethy-
lation of ANKDD1A by 5-aza-2-deoxycytidine-induced ANKDD1A
re-expression at the mRNA and protein levels, and this demethylation
was confirmed by methylation-specific PCR. PG cells are primary cells
derived from glioma patient. *P < 0.05, **P < 0.01
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Moreover, inhibition of GBM cell proliferation by
ANKDD1A was also confirmed by EDU staining assay
(Fig. 2c). The number of EDU-positive cells significantly
decreased upon ANKDD1A transfection (ANK group)
compared to the NC group, suggesting that ANKDD1A
observably inhibited the growth of GBM cells. To test the
tumor suppressive function of ANKDD1A, we analyzed the
growth characteristics and invasion ability (the upper
chambers containing Matrigel coating mean that this assay
measures an invasion phenotype but not migration pheno-
type of cells) in cells stably transduced with lenti-NC-GFP
or lenti-ANK-GFP (Fig. 2d, e). We found that the colonies
formed by the ANK-transfected cells were fewer and
smaller than those formed by the vector-transfected cells,
and the invaded cell numbers were also decreased compared
to the vector-transfected cells. Moreover, to examine the
clinical effect of ANKDD1A-inhibiting glioma proliferation
in more detail, we isolated and cultured primary cells
Fig. 2 Re-expression of ANKDD1A inhibited GBM cell proliferation
and invasion under normoxia. a The successful overexpression of
ANKDD1A-Flag protein in GBM U251 (up)/U87 (down) cells was
detected by immunoblotting. b The effect of ectopic ANKDD1A
expression on GBM U251 and U87 cell proliferation was assessed by
the CCK-8 cell growth assay. ANK cells transfected with Flag-
ANKDD1A plasmid, NC cells transfected with Flag-NC plasmid, **P
< 0.01, ***P < 0.001. c Expression of ANKDD1A inhibited DNA
replication in GBM cells, as determined by EDU staining. The picture
on the right is the enlargement of the white box in the left pictures.
**P < 0.01. d Ectopic expression of ANKDD1A inhibited U251 and
U87 cell clone formation ability, as analyzed by colony formation
assay and crystal violet staining after 14 days; clone numbers were
quantified. *P < 0.05. e U251 and U87 cells were stably transduced
with lenti-vector-GFP or lenti-ANK-GFP; transwell assay was used to
detect the cell invasion ability. ***P < 0.001. f The patient-derived
primary cells were identified by immunofluorescence staining with
GFAP and Nestin antibody. PG-1 represents primary cells that were
derived from high-grade glioma patients. g Transwell assay was used
to detect the invasion inhibitory effect of re-expression of ANKDD1A
in patient-derived primary cells. PG-1, PG-2, and PG-3 are primary
cells derived from glioma patients. *P < 0.05, **P < 0.01, ***P <
0.001
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derived from glioma patients (hereafter referred to as PG).
These cells were identified by immunofluorescence staining
with GFAP and Nestin antibody (Fig. 2f), two known
glioma molecular makers. As shown in Fig. 2g, the re-
expression of ANKDD1A in primary cells reduced cell
invasion in a Matrigel invasion assay (Fig. 2g). Together,
these data provided direct evidence showing that
ANKDD1A inhibited GBM cell proliferation and invasion.
ANKDD1A bound to FIH1 by the conserved ankyrin
repeat domain
To gain new insights into the function of ANKDD1A, the
“BioGRID” (version 3.4) software was utilized to screen for
potential proteins interacting with ANKDD1A. When the
“high stringency” criteria were used, FIH1 and RPGRIP1L
(BioGRID screen result was shown in the supplementary Fig.
S1) were found to be binding partners of ANKDD1A, and
FIH1 was selected for further research. To test whether
ANKDD1A actually interacted with endogenous FIH1, a
Flag-tagged ANKDD1A protein expression vector was
transfected into HEK293 cells. The endogenous FIH1 was co-
immunoprecipitated with ANKDD1A from the cell extract
(Fig. 3a). We also co-expressed green fluorescent protein
(GFP)-FIH1 with red fluorescent protein (RFP)-ANK in
HEK293 cells and analyzed their co-localization by confocal
fluorescence microscopy (Fig. 3b). The confocal results
showed that ANKDD1A and FIH1 co-localized in the cellular
cytoplasm of HEK293 cells. Together, these results confirmed
that ANKDD1A directly binds to FIH1 in cells.
To identify the interacting regions, we subsequently
performed a glutathione-S-transferase (GST) pull-down
assay with ANKDD1A or different domains of
ANKDD1A (Ank: ankyrin repeats domain, DD: death
domain) and GST-fused FIH1, either full-length or different
domains of FIH1 (F-N: N-terminal of FIH1, F-JMJC:
middle domain of FIH1, or F-C: C-terminal of FIH1), as
shown in Fig. 3c, d. The results revealed that full-length
ANKDD1A was pulled down by either the GST-fused full-
length FIH1 (Fig. 3d(ii), line 7, arrow shown) or GST-fused
N-terminal domain of FIH1 (Fig. 3d ii, line 4), whereas the
GST-fused F-JMJC (142-312) or F-C (313-349) was not
able to pull down ANKDD1A (Fig. 3d(ii), line 5 and 6).
These results indicate that the N-terminal domain of FIH1 is
responsible for the interaction with ANKDD1A. In addi-
tion, Fig. 3d(iii) and (iiii) showed that the Ankyrin domain
(residues 1–262) of ANKDD1A, but not the death domain
(residues 263–399), precipitated with both the GST-fused
full-length FIH1 (Fig. 3d(iii), line 7, arrow shown) and the
GST-fused N-terminal domain of FIH1 (Fig. 3d(iii), line 4,
arrow shown). Collectively, these data demonstrated that
ANKDD1A binds to FIH1 directly, through the ankyrin
domain of ANKDD1A and the N-terminal domain of FIH1.
ANKDD1A suppressed the expression of hypoxic
response genes by inhibiting HIF1α transcriptional
activity in the hypoxia microenvironment
The transcriptional activity of HIF1α is tightly regulated by
FIH1, which hydroxylates the Asn803 residue of the HIF1α
C-TAD (C-terminal transcription activation domain) and
thereby blocks the interaction of HIF1α with the p300/CBP
co-activator. Hence, we speculated that ANKDDA might
participate in the HIF1α signaling pathway by interacting
with FIH1. First, we investigated whether ANKDD1A
affected hypoxic response gene expression and found that
under low oxygen conditions (1% oxygen concentration),
ANKDD1A reduced the mRNA expression level of HIF1α
responsive genes such as Glut1, BNIP3, PHD3, LDH-A,
CA9, and PGK1 in GBM U251 and U87 cells (Fig. 4a, b).
Subsequently, we constructed a pGL3-CA9 firefly lucifer-
ase (FLuc) reporter vector driven by the promoter region of
CA9, which contains hypoxia response elements (HRE).
When both pcDNA3.1-ANKDD1A and pGL3-CA9 plas-
mids were co-transfected in HEK293T and astrocytoma
cells, we found that the ectopic expression of ANKDD1A
dramatically reduced the FLuc activity under hypoxic stress
but only slightly decreased it under normoxia (Fig. 4c). We
also used a classic HRE-luciferase vector to monitor the
transcriptional activity of HIF1α when pcDNA3.1-
ANKDD1A or pCDNA3.1-FIH1 was transfected in glioma
cells under hypoxia. The results showed that both
ANKDD1A and FIH1 directly reduced HIF1α transcrip-
tional activity. Moreover, the relative luciferase activity was
the lowest when ANKDD1A was co-expressed with FIH1
(Fig. 4d), suggesting that ANKDD1A suppressed HIF1α
transcriptional activity by interacting with FIH1.
In line with this result, ANKDD1A also markedly
decreased the mRNA expression levels of HIF1α target
genes when ANKDD1A was transfected in three types of
primary glioma cells (Fig. 4e). The overexpression of
ANKDD1A also inhibited the protein expression of HIF1α
target genes under hypoxia, such as LDH-A, Glut1, CA9,
PHD3, and PGK1 (Fig. 4f). Taken together, ANKDD1A
decreased the expression of hypoxia response genes by
reducing transcriptional activity of HIF1α at low oxygen
conditions.
ANKDD1A increased HIF1α ubiquitinated
degradation through upregulating FIH1 and PHD2
in the hypoxia microenvironment
Next, we examined the effect of ANKDD1A on HIF1α
expression in GBM cells. Under normoxia, we barely
detected the expression of HIF1α. However, under hypoxia,
HIF1α expression was markedly decreased in U251 and
U87 cells transfected with ANKDD1A (Fig. 5a and
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Fig. 3 ANKDD1A interacted with FIH1. a HEK293(up)/U251(down)
cells were transfected with Flag-ANKDD1A. Co-immunoprecipitation
showed the interaction between ANKDD1A and endogenous FIH1 in
HEK293/U251 cells. b The confocal fluorescence of HEK293 cells co-
transfected with pDsRed-ANKDD1A and pEGFP-FIH1. The merged
image shows the co-localization of ANKDD1A and FIH1 in the
cytoplasm. c Schematic diagrams of ANKDD1A (left)/FIH1(right) and
truncated domains. Full-length ANKDD1A, domain-Ank, and
domain-DD were generated as Flag-tagged fusion proteins. Full-length
FIH1, F-N domain, JMJC domain, and F-C domain were generated as
GST-fusion proteins expressed in prokaryotic bacteria. d GST pull-
down assays showed that the ankyrin domain of ANKDD1A pulled
down FIH1, and the F-N domain was necessary for the interaction of
FIH1 with ANKDD1A. i Upper left: BL21 (DE3) bacteria expressed
GST. GST-fusion full-length FIH1 or different domains were
precipitated by glutathione–sepharose 4B beads. Immunoprecipitated
proteins were analyzed by western blot with anti-GST antibody. Arrow
indicated each fusion protein. ii Upper right: p3 × Flag-cmv-10-
ANKDD1A plasmid was transfected into HEK293 cells. After 48 h,
cell lysate was incubated with GST-FIH1 full-length protein or dif-
ferent GST-FIH1 domains. Arrow indicated Flag-ANKDD1A protein.
iii Bottom left: p3 × Flag-cmv-10-Ank-domain of ANKDD1A plasmid
was transfected into HEK293 cells. After 48 h, cell lysate was incu-
bated with each GST-FIH1 full-length protein or different GST-FIH1
domain for GST pulldown. Arrow indicated Flag-Ank domain protein.
iiii Bottom right: p3 × Flag-cmv-10-DD-domain plasmid was trans-
fected into HEK293 cells. After 48 h, cell lysate was incubated with
each GST-FIH1 full-length protein or different GST-FIH1 domains for
GST pulldown. Arrow indicated Flag-DD domain protein
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supplementary Fig. S2a). We also used confocal fluores-
cence to examine the potential effects of ANKDD1A on
HIF1α localization or expression and revealed that HIF1α
remained exclusively in the nucleus under hypoxia condi-
tions, but when in the presence of ANKDD1A expression,
the HIF1α staining signal disappeared (Fig. 5b). These data
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indicated that ANKDD1A regulated HIF1α protein levels
under hypoxia conditions.
Then, we wanted to know whether ANKDD1A altered
the stability of HIF1α protein. By examining the half-life of
HIF1α protein with cycloheximide treatment, a protein
synthesis inhibitor, we observed that ANKDD1A shortened
the half-life of HIF1α under hypoxia (Fig. 5c), suggesting
that ANKDD1A decreased the protein levels of HIF1α
through increasing its instability. We also examined the
effect of overexpressing ANKDD1A on HIF1α ubiquiti-
nated modification, since HIF1α is ubiquitinated by pVHL
E3 ligase and rapidly degraded by the proteasome under
normoxia [24]. The ubiquitinated modification of HIF1α
was also increased by transfected ANKDD1A (Fig. 5d).
The stability of HIF1α is known to be regulated by
PHD2, a proline-hydroxylase, and the dysregulation of
FIH1 also accounts for the decreased half-life of HIF1α
[25]. Consistent with this, we found that ANKDD1A
expression increased FIH1 and PHD2 expression in GBM
cells under hypoxia and normoxia (Fig. 5e and supple-
mentary Fig. S2b). To test the mechanism of PHD2 and
FIH1 upregulation, U251 cells transduced with ANKDD1A
or vector were treated with CHX, and the half-life of PHD2
and FIH1 was analyzed. The results showed that the protein
half-lives of PHD2 and FIH1 were increased in
ANKDD1A-expressing U251 cells compared to vector-
U251 cells (Fig. 5f). Treating GBM cells under hypoxia
with MG132 (proteasome inhibitor) or IOX2 (PHD2-spe-
cific inhibitor), we found that MG132 or IOX2 increased
the HIF1α protein level but had no noticeable effect on
FIH1 (shown in Supplementary Fig. S3), suggesting that
HIF1α was degraded in the PHD2-dependent
ubiquitin–proteasome degradation pathway. In addition,
we unexpectedly found that the expression of HIF1α was
significantly decreased by FIH1 in GBM cells under
hypoxia conditions (Fig. 5g). Although both MG132 and
IOX2 restored the expression of HIF1α with overexpression
of ANKDD1A, only MG132 treatment, and not IOX2
treatment, restored HIF1α expression when FIH1 was
overexpressed, indicating that FIH1 mediated the degrada-
tion of HIF1α in a PHD2-independent,
ubiquitin–proteasome degradation pathway. Finally, we
found that the ubiquitinated modification of HIF1α was
decreased when silencing PHD2 or FIH1 in U251 cells that
stably expressed ANKDD1A (Fig. 5h). Taken together,
these data indicated that ANKDD1A shortened the half-life
of HIF1α through increasing FIH1 and PHD2 expression in
GBM cells under hypoxia conditions.
ANKDD1A disturbed the tolerance of GBM cells to
hypoxia by inhibiting cell metabolism and
autophagy
Hypoxia is an almost universal hallmark of solid tumors,
including glioma, and the HIF1α signal pathway plays an
important role in cell response to the hypoxic environment
[26]. HIF1α activation would allow for the adaptation of
glioma cells to hypoxia and survival. We next examined the
effects of ANKDD1A on GBM hypoxic tolerance. Of note,
the re-expression of ANKDD1A significantly decreased
tumor cell invasion under normoxia (Fig. 2c) and hypoxia
conditions (Fig. 6a). In agreement with this, EDU staining
assay confirmed the inhibition of cellular DNA replication
by ANKDD1A in normoxia (Fig. 2d) and hypoxia envir-
onments (Fig. 6b). Importantly, we found that the sup-
pression function of ANKDD1A was stronger under
hypoxia than normoxia in GBM cells, for the significant p
value is much smaller in hypoxic conditions compared to
the normoxic conditions.
Metabolic behaviors were changed in the hypoxia
microenvironment, such as increased glycolysis and lactate
metabolism, to prompt cells to adapt to hypoxic stress [27].
Thus, we next examined whether ANKDD1A causes
impairment of glucose metabolism in GBM cells under
hypoxia. As expected, GBM cells transfected with
ANKDD1A had lower glucose uptake rates and lower
levels of LDH activity compared to control (NC) under
hypoxia (Fig. 6c). At the same time, ANKDD1A over-
expression inhibited the proliferation (Fig. 6b) and autop-
hagy (Fig. 6d) of both U251 and U87 cells in hypoxia
conditions. Autophagy may be a self-rescue of tumor cells
in hypoxia, and inhibition of autophagy may cause tumor
cell death [28]. Consistently, the overexpression of
ANKDD1A increased cell apoptosis under hypoxia in
astrocytoma. The above data support the hypothesis that
ANKDD1A significantly disturbs the tolerance of GBM
Fig. 4 ANKDD1A reduced HIF1α transcriptional activity under
hypoxia. a–b The overexpression of ANKDD1A decreased the
expression of hypoxia response genes (GLUT1, LDH-A, CA9, PHD3,
and PGK1) under hypoxia in U251/U87 cells. *P < 0.05, **P < 0.01,
***P < 0.001. c CA9 promoter was cloned into the pGL3-enhancer
luciferase reporter. Luciferase reporter assays were performed 48 h
after transfection with the indicated pGL3-REPORT plasmids and a
Renilla transfection control plasmid that was co-transfected with
ANKDD1A or a relevant scrambled control under normoxia or
hypoxia. The expression of ANKDD1A dramatically decreased FLuc
activity under hypoxic stress but only slightly decreased it under
normoxia. *P < 0.05. d The HRE-luciferase reporter was used to
confirm the inhibition of ANKDD1A in regulating HIF1α transcrip-
tional activity. Luciferase activity was the lowest when co-
overexpression of ANKDD1A and FIH1 was achieved. **P < 0.01,
***P < 0.001. e Hypoxia response gene expression was detected in
astrocytoma patient-derived primary cells. The overexpression of
ANKDD1A decreased mRNA expression levels of HIF1α target genes
under hypoxia. *P < 0.05, **P < 0.01, ***P < 0.001. f Western blot
detected the expression of three HIF1α transcriptional activity-
dependent genes after the overexpression of ANKDD1A in U251
cell under hypoxia conditions. The overexpression of ANKDD1A also
inhibited the protein expression of HIF1α target genes under hypoxia
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cells to hypoxia, decreases cellular glucose and lactate
metabolism, and induces cell apoptosis.
ANKDD1A expression suppressed tumor growth and
improved survival
To evaluate if ANKDD1A possessed in vivo anti-tumor
capabilities, we established a subcutaneous transplantation
tumor model in nude BALB/c mice using U251 cells. Nude
mice were inoculated with U251 cells with a lentivirus-
encoded ANKDD1A or control in the armpit of left fore-
limb. After 45 days, tumor volume was measured in each
group. As shown in Fig. 7, the tumor volumes were smaller
in mice engrafted with lenti-ANK U251 cells than in ani-
mals implanted with lenti-NC U251 cells (Fig. 7a). More-
over, the immunohistochemical staining revealed that lenti-
NC tumors showed increased expression of a proliferation
marker (Ki67) and HIF1α staining compared with lenti-
ANK tumors (Fig. 7b). To assess whether ANKDD1A
expression affected intracranial tumor growth, stereotactic
intracranial injection of lenti-ANK U251 cells or lenti-NC
U251 cells in immunocompromised mice was conducted.
Lenti-NC tumors were strikingly more invasive and larger,
generating bigger vessels in the peritumoral region that
were evident on histological examination (Fig. 7c). More-
over, survival analysis showed mice intracranially engrafted
with lenti-ANK U251 cells survived (p < 0.05) longer than
animals implanted with lenti-NC U251 cells (Fig. 7d). Our
studies indicated that ANKDD1A expression inhibited
tumor growth in vivo and extended mouse overall survival.
Discussion
In previous studies, we found a new hypermethylated gene
in glioma, ANKDD1A, which is an unnoticed gene with
unknown function. In this study, we first verified that
ANKDD1A is frequently silenced or has lower expression
level in glioma mainly due to its abnormal promoter CpG
methylated modification. Ectopic expression of ANKDD1A
inhibits the proliferation and invasion of GBM cells.
Although we have investigated the mechanism of
ANKDD1A standard glioma cell lines, because of some
important limitations of cell lines and primary cell cultures
were well acknowledged to reflect the tumor biology of
glioblastoma patients. We also separated patient-derived
primary cell for experiments in our study. The re-expression
of ANKDD1A also inhibits the proliferation and invasion of
patient-derived primary cells under normoxia and hypoxia
microenvironments. Therefore, ANKDD1A could act as a
tumor suppressor gene in GBM, especially under hypoxia
conditions.
ANKDD1A is located at 15q22.31 and contains nine
ankyrin repeats and one death domain. The ankyrin repeat is
one of the most common protein–protein interaction motifs
in nature. Ankyrin repeats are tandemly repeated modules
of ~33 amino acids. The repeat has been found in proteins
of diverse functions, including transcriptional activators,
transporters, inflammatory responses, and signal transducers
[18–21]. The death domain (DD) is a homotypic protein
interaction module composed of a bundle of six alpha
helices. DD is related in sequence and structure to the death
effector domain (DED) and the caspase recruitment domain
(CARD), which work in similar pathways and show similar
interaction properties. Some DD-containing proteins are
involved in the regulation of apoptosis and inflammation
through their activation of caspases and NF-kappaB, which
typically interacts with TNF (tumor necrosis factor) cyto-
kine receptors [29, 30]. We first found and authenticated
that FIH1 directly binds ANKDD1A. FIH1 is an oxygen-
dependent asparaginyl hydroxylase that was initially
reported to regulate the activity of HIF1α [31]. In addition
to the function as HIF1α inhibitor, the FIH1 gene has also
been associated with hydroxylation events in a range of
certain ankyrin repeat domain (ARD)-containing proteins,
including members of the IκB and Notch families [32–35].
FIH1 has been described as a regulator of the Notch path-
way, metabolism and apoptosis [36, 37]. In this study, we
confirmed that FIH1 interacts with ANKDD1A, and the
ankyrin repeat domain of ANKDD1A directly binds to the
N-terminal domain of FIH1. FIH1 catalyzes asparagine
Fig. 5 ANKDD1A reduced HIF1α stability by upregulating FIH1 and
PHD2. a Western blot analysis for HIF1α upon the overexpression of
ANKDD1A in U251 or U87 glioma cells. ANKDD1A significantly
decreased HIF1α under hypoxia but had no effect on HIF1α under
normoxia. b U251 cells were transfected with red fluorescent protein
(RFP)-ANKDD1A under hypoxic conditions. Cells were stained with
anti-HIF1α antibody (green) as indicated. The nuclei were stained with
DAPI (blue). Scale bar, 20 μm. c Western blot analysis for measure-
ment of the half-life of HIF1α after treatment with cycloheximide in
U251 cells with or without ANKDD1A transfection, ANKDD1A
shortened the half-life of HIF1α. d HIF-1α ubiquitination was assessed
by anti-Flag antibody in the presence of MG132 when Flag-HIF1α,
HA-ubiquitin, and pCDNA-ANKDD1A or Vector were co-transfected
into U251/293 cells. ANKDD1A increased HIF1α ubiquitination. e
Western blot analysis for PHD2 and FIH1 when ANKDD1A was
transfected in U251 cells or PG-1 patient-derived primary cells.
ANKDD1A increased PHD2 and FIH1 expression. f Western blot
analysis for measurement of the half-life of PHD2 and FIH1 after
treatment with cycloheximide in U251 cells with or without
ANKDD1A transfection. ANKDD1A prolonged the half-life of PHD2
or FIH1. g Both the overexpression of ANKDD1A and FIH1
decreased the expression of HIF1α. MG132 or IOX2 restored the
expression of HIF1α when ANKDD1A was overexpressed, but only
MG132 treatment restored HIF1α expression when cells were trans-
fected with FIH1. h HIF-1α ubiquitination was assessed by an anti-
HIF-1α antibody. The ubiquitinated modification of HIF1α was
decreased when silencing PHD2 or FIH1 in U251 cells stably
expressing ANKDD1A
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Fig. 6 ANKDD1A significantly impaired GBM cell adaptation to
hypoxia environments. a The inhibition of invasion by ANKDD1A in
GBM cells under low oxygen culture conditions. ANKDD1A sig-
nificantly decreased GBM cell invasion in hypoxia. ***P < 0.001. b
EDU staining showed that ANKDD1A inhibited DNA replication of
GBM cells. The picture on the right is the enlargement of white box of
the left pictures. **P < 0.01. c ANKDD1A decreased cellular glucose
consumption, lactic acid production, and cell proliferation under
hypoxia. *P < 0.05, **P < 0.01. d Expression of the autophagy-related
proteins ATG5, ATG7, ATG12, and LC3 was downregulated by
ANKDD1A in U251/U87 cells under hypoxia. e Apoptosis was
detected by flow cytometry. ANKDD1A increased GBM cell apop-
tosis under hypoxia. *P < 0.05
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hydroxylation of HIF1α, which blocks the association of
HIF1α with CBP/p300 transcriptional coactivators, thereby
reducing the transcription activity of HIF1α. We propose
that ANKDD1A regulates the activity of HIF1α. Supporting
this hypothesis, our findings demonstrated that ANKDD1A
significantly decreased transcriptional activity of HIF1α in
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GBM cells under hypoxia. Moreover, the relative luciferase
activity controlled by the transcriptional activity of HIF1α
was the lowest upon co-overexpression of ANKDD1A and
FIH1, suggesting that ANKDD1A suppressed HIF1α tran-
scriptional activity by interacting with FIH1. Since tumor
cells grow rapidly and need to consume much oxygen for
cellular respiration, insufficient blood vessel growth rate
leads to hypoxic regions in tumors, and hypoxia is con-
sidered a harsh condition for tumor cells. Under the stressful
conditions, HIF1 activation would allow tumor cells to
adapt to hypoxia and survive [38]. It has been demonstrated
that HIF1α is overexpressed in a broad spectrum of human
malignancies [39]. Furthermore, HIF1α accumulation has
been associated with poor patient survival [40]. The over-
expression of HIF1α was also well described in glioma [41].
HIF1α activates target gene expression involved in vascu-
larization, glucose transport, energy metabolism, and
growth and metastasis, including VEGF, PDK1, Cyclin-D2,
and CA9, and makes glioma cells adapt to hypoxic envir-
onments. Blocking HIF1α accumulation may be a ther-
apeutic strategy for tumors. Generally, HIF1α is
hydroxylated on specific proline residues by prolyl hydro-
xylases (PHD) and becomes a substrate for protein von
Hippel–Lindau (pVHL) E3 ligase for proteasome degrada-
tion under normoxic conditions [42]. However, not only
hydroxylation but also other posttranslational modifications,
including SUMOylation, acetylation, methylation and
phosphorylation [43–46], are known to regulate HIF1α
stability. In our research, we first found that ANKDD1A
plays an important role in regulating the stability of HIF1α
in astrocytoma cells under hypoxic conditions. The over-
expression of ANKDD1A also decreased HIF1α protein
level, while treatment with MG132 blocked this effect,
suggesting that ANKDD1A mediates the degradation of
HIF1α in an ubiquitin-dependent manner. Of note, the FIH1
protein level was increased in GBM cells when ANKDD1A
was expressed. Therefore, we proposed that the increase of
FIH1 makes HIF1α more susceptible to degradation via
non-PHD-mediated degradation. We provided evidence that
FIH1 leads to the HIF1α destabilization under hypoxic
conditions, but this effect was not blocked by IOX2, which
is a direct PHD enzyme inhibitor. The most likely expla-
nation is that FIH1 directly interacts with VHL [47]. The
accumulation of FIH1 facilitates the binding between FIH1
and HIF1α, thus resulting in the degradation of HIF1α.
Taken together, our findings demonstrated that ANKDD1A
degraded HIF1α protein through interacting with FIH1 in
GBM cells.
Extensively studied as part of HIF1 signaling, tumor cell
adaptation to hypoxia benefited from metabolic repro-
gramming [48]. HIF1α functions as a master regulator for
cellular and homeostatic response to hypoxia by activating
transcription of many genes that facilitate metabolic adap-
tation to hypoxia, such as GLUT1, PDK1, and LDH-A.
Under hypoxic conditions, glycolytic rates are enhanced,
resulting in an increase in lactate production by cells
expressing HIF1α. Autophagy is a cellular biological pro-
cess that degrades unnecessary or dysfunctional proteins
and organelles to maintain nutrient and energy homeostasis
during stress conditions [49]. It has been reported that
hypoxia induces autophagy in an HIF1-dependent manner
[50, 51]. Our data also indicated that ANKDD1A reduced
tumor cell glucose uptake and lactic acid production under
hypoxia, inhibited cell autophagy, induced apoptosis, and
increased the glioma patient survival.
In hypoxia, HIF1α stable existence and activation allow
tumor cells to adapt to hypoxia and survival. As HIF1α is
degraded and made non-functional by certain degradation
mechanism under normoxia, ANKDD1A cannot function
through HIF1α; therefore, it must have another function
pathway under normoxia. Although we did not mention the
mechanism for the biological effects of ANKDD1A in
normoxia, it has been reported that FIH1 expression
decreased the oncogenic potential of HNSCC cells in
nomorxia [52]. Since FIH1 is located at chromosome
10q24, which is often deleted in some cancers [41], FIH1
might can also act as a tumor suppressor gene. Moreover,
another article proposed PHD2 as a potential tumor sup-
pressor in breast cancer [53]. Our results indicated that the
overexpression of ANKDD1A upregulated FIH1 and PHD2
expression in both normoxia and hypoxia. We suspect that
the upregulation of FIH1 and PHD2 will act as a tumor
suppressor in GBM under normoxia; this may be the
mechanism for ANKDD1A biological effects in normoxia.
In conclusion, this study demonstrates that ANKDD1A
is a functional tumor suppressor gene, especially under a
hypoxia microenvironment. ANKDD1A directly interacts
with FIH1 and inhibits both the transcriptional activity of
HIF1α and HIF1α-dependent gene expression by upregu-
lating FIH1. In addition, ANKDD1A also decreased the
half-life of HIF1α by upregulating FIH1, decreased glucose
uptake and lactate production, inhibited glioma cell autop-
hagy, and induced apoptosis in GBM cells under hypoxia.
Moreover, ANKDD1A is highly frequently methylated in
Fig. 7 ANKDD1A expression suppressed tumor growth and improved
survival. a The subcutaneous transplantation tumor model in nude
BALB/c mice was established using U251 cells that were stably
transduced with lenti-NC or lenti-ANK. The tumor size was measured.
*P < 0.05. b IHC analysis of tumor sections showed the expression of
Flag-ANK, Ki67, and HIF1α. c Representative images for mice brains
that received injection of U251 cells overexpressing ANKDD1A
(ANK) versus control (NC). **P < 0.01. d Kaplan–Meier survival
curves of mice that were implanted with U251 cells overexpressing
ANKDD1A (ANK) versus control (NC). *P < 0.05. e Model of the
ANKDD1A-mediated pathway in regulating HIF1α stability in GBM
cells under hypoxia conditions
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glioma, and the tumor-specific methylation of ANKDD1A
indicated that it could be used as a potential epigenetic
biomarker and possible therapeutic target.
Materials and methods
Tissue samples
Primary glioma samples and normal brain tissues were
obtained from the Department of Neurosurgery, Xiangya
Hospital, Hunan, China. This study was approved by the
hospital institutional review board, and written informed
consent was obtained from all patients. All the protocols
were reviewed by the Joint Ethics Committee of the Central
South University Health Authority and performed following
national guidelines. Primary tumor and normal brain tissues
were frozen in liquid nitrogen and stored until total RNAs
or genomic DNA were extracted.
Cell lines culture and reagents
Human glioblatoma cell lines U251 and Human Embryonic
Kidney (HEK) 293 cells were maintained in DMEM med-
ium with high glucose and sodium pyruvate, supplemented
with 10% fetal bovine serum and antibiotics (100 units/ml
penicillin and 100 mg/ml streptomycin). Human glio-
blatoma cell lines U87 were maintained in MEM medium
supplemented with 10% fetal bovine serum. Cells were
incubated at 37 °C in a humidified atmosphere of 5% CO2
in air. Cells were authenticated that it origins from ATCC
by short-tandem repeat profiling. Antibodies against HIF1α
(20960-1-AP), GST(66001-1-Ig), and HA(51064-2-AP)
were purchased from ProteinTech. Antibodies against FIH1
(sc-26219) were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). FLAG (F1804) was purchased
from Sigma-Aldrich. Antibodies against CA9 (No.
D120346), GLUT1 (No. D160433), LDH-A (No.
D199841), and PHD2 (No. D122872) were purchased from
Sangon Biotech. Antibodies against ATG5 (D5F5U), ATG7
(D12B11), ATG12 (D88H11), and LC3A/B (D3U4C) were
purchased from Cell Signaling Technology.
Primary astrocytoma cell culture
All samples collected had the informed consent of the
patients, and all experiments using human tissues were
approved by the Joint Ethics Committee of the Central
South University Health Authority. Primary glioma samples
(details in supplementary Table S1) were minced with
GentleMACS Dissociator (Miltenyi Biotec, Gladbach,
Germany) and digested with 0.25% trypsin at 37 °C for
30 min. Digestion was stopped by adding trypsin inhibitor,
and cells were passed through a 40 μm nylon cell strainer
(Corning, 352340) to obtain single-cell suspensions. Cells
were cultured in DMEM/F12 containing 10% FBS. Glioma
cells were tested with GFAP, nestin staining and sub-
cutaneous implantation of nude mice.
Methylation-specific PCR and bisulfite genomic
sequencing
Genomic DNA was bisulfite treated and conversed by EZ
DNA Methylation-Lightning™ Kit according to the man-
ufacturer’s instructions. Then, the bisulfite-modified DNA
was used for further experiments. For the BSP, 2.5 U of Taq
mix (Promega) and 2 μl of 1 mM forward and reverse pri-
mers were used in a 50-μl total reaction volume. Subse-
quently, 100 ng of bisulfite-treated DNA was used as the
template for PCR. The PCR cycles were as follows: 95 °C
for 5 min, followed by 45 cycles at 95 °C for 0.5 min,
59.98 °C for 0.5 min and 72 °C for 1 min, followed by a
final extension at 72 °C for 5 min. The PCR products were
purified via gel extraction from a 1% agarose gel and ligated
into the pGEM-T vector (takara) following the manu-
facturer’s instructions. The ligation products were used to
transform competent Escherichia coli cells (strain JM109)
using standard procedures, and blue/white screening was
used to select a minimum of five bacterial transformants
(clones). The ANKDD1A promoter of the positive clones
was sequenced by Biosune (Changsha, China) and BGI
(Guangzhou, China). The increase in the methylation for
each sample was calculated as the percentage of unmethy-
lated CpG dinucleotides from the total number of CpG
dinucleotides that were analyzed. For the MSP, 2 U of Taq
mix (Promega) and 0.8 μl of 1 mM forward and reverse
primers were used in a 20-μl total reaction volume. Sub-
sequently, 50 ng of bisulfite-treated DNA was used as the
template for PCR. The PCR cycles were as follows: 95 °C
for 5 min, followed by 40 cycles at 95 °C for 0.5 min,
51.5 °C for 0.5 min, and at 72 °C for 0.5 min, followed by a
final extension at 72 °C for 5 min. The PCR products were
separated on 1% agarose gels and analyzed via Sybrsafe
staining.
Plasmid vector
HIF1α-pcDNA3, HA-Ubiquitin, HRE-luciferase, and
pEGFP-FIH1 plasmid were purchased from Addgene.
ANKDD1A-pcDNA3.1 plasmid was purchased from Vig-
ene Biosciences (Shandong, China). ANKDD1A was
cloned into pDsRed-N1 plasmid. HIF1α was cloned into
p3 × flag-cmv-10 plasmid. Upstream promoter regions
(−2000 bp from TSS) of the CA9 gene were amplified from
U251 cells gDNA by PCR, PCR fragments were digested
with Kpn1/HindIII and linked to the pGL3-Enhancer Vector
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(Promega, WI, USA) to create plasmid pGL3-CA9. The
sequences and the orientation of the cloned fragments were
confirmed by direct DNA sequencing. Different domains of
ANKDD1A (ARK domain, DD domain) were cloned into
p3 × flag-cmv-10 plasmid by PCR and different domains of
FIH1 (F-N, F-JMJC, F-C) were cloned into pGEX-4T-2
plasmid by PCR described above.
RNA isolation and qRT-PCR
RNA was isolated from harvested cells with Trizol reagent
according to the manufacturer’s instruction (Invitrogen, CA,
USA), and then used for first-strand cDNA synthesis using
RevertAid RT Reverse Transcription Kit (Thermo Fisher).
Real-time PCR reactions were performed using SYBR
Premix DimerEraser (Takara, Dalian, China) and the rela-
tive expression of genes was normalized using GAPDH as a
housekeeping gene.
Immunoprecipitation and immunoblotting
For immunoprecipitation, cells were harvested, washed with
ice-cold PBS buffer, lysed in IP buffer (25 mM Tris pH 7.5,
150 mM NaCl, 1% Triton X-100, 1 mM EDTA), followed
by centrifugation for 15 min at 12,000 r.p.m. Cell lysates
were incubated with indicated antibodies at 4 °C for over-
night. Forty microlitres protein A/G after wash twice with
IP buffer were then added to the reaction mixtures and
incubated for 4 h at 4 °C. After rapid centrifugation, the
resulting Sepharose pellets were washed five times with IP
buffer and boiled for 10 min with addition of 2× SDS
loading buffer, immunoprecipitated proteins were analyzed
by SDS-PAGE. For immunoblotting, cells were harvested,
washed with ice-cold PBS buffer, lysed in RIPA buffer
(100 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA, 1%
Triton X-100, 1% deoxycholate acid, 0.1% SDS, 2 mM
phenylmethylsulfonyl fluoride, 1 mM sodium orthovana-
date, 2 mM DTT, 2 mM leupeptin, 2 mM pepstatin), and
centrifuged at 12,000 rpm at 4 °C for 15 min. Protein lysates
were fractionated by SDS-polyacrylamide gel electrophor-
esis, transferred onto PVDF membranes (Merck Millipore,
Germany), and then incubated with indicated primary
antibodies, washed, and probed with HRP-conjugated sec-
ondary antibodies. ECL Detection System (Merck Milli-
pore, Germany) was used for signal detection.
Quantification of western blotting results was shown in
Supplementary file.
Pull-down assay
GST-fusion proteins containing various regions of FIH1
were expressed in BL21 (DE3) bacteria with pGEX-4T-2
vector and were purified. Flag-tagged various sections of
ANKDD1A were transfected into HEK293 cell and lysed in
the IP buffer. Then, the lysate was incubated for 4 h with
GST-tagged proteins and glutathione–Sepharose 4B beads.
The beads were subsequently washed four times in the IP
buffer. Precipitates were separated by SDS-PAGE and
detected by western blot analysis.
Immunofluorescence
The cultured cells were plated on coverslips and transfected
with indicated plasmids. After transfection for 48 h, the cells
were washed three times with ice-cold PBS, fixed in 4%
paraformaldehyde (PFA) at room temperature for 30 min.
Cells were then washed two times with 0.1% PBS-T. For
permeabilization, cells incubated with 0.25% Triton X-100
in PBS for 15 min and washed two times with 0.1% PBS-T.
Cells were incubated in blocking solutions (normal goat
serum), to block nonspecific binding of the antibody for
30 min, and incubated in primary antibodies diluted in PBS.
After four washes with 0.1% PBS-T, cells were incubated in
secondary antibodies for 1 h. After washed three times,
nuclear staining was performed with DAPI (cwbiotech,
Beijing, China). Coverslips were mounted and imaged by
fluorescence microscope.
Luciferase reporter assay
U251 or HEK293 cells were seeded into a 48-well plate for
luciferase assays. After overnight culture, cells were co-
transfected with pGL3-CA9 and equal amounts of
ANKDD1A or vector. The pRL-TK control vector was
transfected as a control. After 24 h of culturing under
hypoxia, luciferase assays were performed using the Dual
Luciferase Reporter Assay System (Promega, WI, USA).
Firefly and Renilla reniformis luciferase activities were
measured 24 h later. Experiments were performed in three
independent replicates.
Xenograft tumor model
All animal experiments were approved by the Animal Care
and Use Committee of Central South University. For the
intracranial implantation mouse model, U251-NC and
U251-ANK cells were collected, resuspended at (1 × 106)
cells in 4 μl of serum-free medium per animal, and then
stereotactically injected into the striatum (1.0 mm anterior
and 2.0 mm lateral from Bregma suture and 3.5 mm below
the pial surface) of nude mice. For subcutaneous tumor
formation, cells (2 × 106) with 100 μl of serum-free medium
were injected subcutaneously at the left flank into nude
mice. A total of 24 mice were used for the intracranial
xenograft tumor model, including ANK overexpression
groups and control groups. After intracranial injection, two
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mice in each group were died, and then five mice in each
group were used for survival analysis, which was calculated
by the Kaplan–Meier method. Five mice in each group were
killed after 45 days for IHC and HE staining. HE staining
was used to show the intracranial tumor size. Tumor
volumes were determined according to the following for-
mula: A × B2/2, where A is the largest diameter and B is the
diameter perpendicular to A.
Statistical analysis
Exclusion and inclusion criteria for animal studies were not
used in this study. The investigators were not blinded to the
group assignment and the outcome assessment. Data are
presented as the means ± SD from at least three separate
experiments, and the data were analyzed with GraphPad
Prism 5 (La Jolla, CA, USA). Differences between the
variables of the two groups were examined by Student’s t
test, and one-way ANOVA was used to evaluate the dif-
ferences between the variables of multiple groups. OS
curves of the xenograft tumor model mice were calculated
by the Kaplan–Meier method. The results were considered
significant when P < 0.05 was obtained.
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